JP2019535645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535645A5
JP2019535645A5 JP2019513898A JP2019513898A JP2019535645A5 JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5 JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5
Authority
JP
Japan
Prior art keywords
chimeric polypeptide
cell
polypeptide according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050787 external-priority patent/WO2018049237A1/en
Publication of JP2019535645A publication Critical patent/JP2019535645A/ja
Publication of JP2019535645A5 publication Critical patent/JP2019535645A5/ja
Pending legal-status Critical Current

Links

JP2019513898A 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物 Pending JP2019535645A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662385656P 2016-09-09 2016-09-09
US62/385,656 2016-09-09
US201762553048P 2017-08-31 2017-08-31
US62/553,048 2017-08-31
PCT/US2017/050787 WO2018049237A1 (en) 2016-09-09 2017-09-08 Methods and compositions for treatment of lafora disease

Publications (2)

Publication Number Publication Date
JP2019535645A JP2019535645A (ja) 2019-12-12
JP2019535645A5 true JP2019535645A5 (enExample) 2020-10-22

Family

ID=61562328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513898A Pending JP2019535645A (ja) 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物

Country Status (7)

Country Link
US (1) US10781433B2 (enExample)
EP (1) EP3509614A4 (enExample)
JP (1) JP2019535645A (enExample)
CN (1) CN109963576A (enExample)
AU (1) AU2017322483A1 (enExample)
CA (1) CA3036524A1 (enExample)
WO (1) WO2018049237A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
KR20220049568A (ko) * 2019-08-22 2022-04-21 더 리전츠 오브 더 유니버시티 오브 캘리포니아 엔젤만 증후군의 치료를 위한 ube3a
KR102814185B1 (ko) 2023-07-20 2025-06-12 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
WO2025018822A1 (ko) 2023-07-20 2025-01-23 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6166041B2 (ja) 2009-06-15 2017-07-19 バレリオン セラピューティクス, エルエルシー ミオチューブラリン1(mtm1)ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物
US20130273026A1 (en) 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
HK1220980A1 (zh) * 2013-02-20 2017-05-19 Valerion Therapeutics, Llc 用於治疗庞贝氏症的方法和组合物
JP2016513114A (ja) * 2013-02-20 2016-05-12 バレリオン セラピューティクス, エルエルシー フォーズス・コリ病の処置のための方法および組成物
US10221250B2 (en) * 2014-01-13 2019-03-05 Valerion Therapeutics, Llc Internalizing moieties
WO2015192092A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
US10501554B2 (en) * 2014-08-27 2019-12-10 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019535645A5 (enExample)
JP2012529891A5 (enExample)
JP2011501951A5 (enExample)
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP2020511949A5 (enExample)
JP2017527272A5 (enExample)
JP2020531002A (ja) 獣医学用igg fc変異体
JP2020505034A5 (enExample)
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
EP2646472B1 (en) Covalently dimerized bivalent binding agents
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
CN109563158A (zh) 抗补体因子bb抗体以及其用途
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
HRP20161449T1 (hr) Genski proizvodi koji su diferecijalno izraženi u tumorima i njihova primjena
US20140271640A1 (en) FGF-10 Complexes
KR20240029769A (ko) 융합단백질 및 이의 응용
WO2014089507A1 (en) Fgf-10 complexes
WO2020093789A1 (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
JP7411264B2 (ja) 新規抗pad2抗体
US8207307B2 (en) Antibodies against human CCN1 and uses thereof
KR20220022899A (ko) 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
Aatsinki et al. An alternative use of basic pGEX vectors for producing both N-and C-terminal fusion proteins for production and affinity purification of antibodies
TW200827441A (en) Method for preparing fusion protein
TWI857985B (zh) 胜肽之結合物及其製造方法